Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Remogliflozin (Remo), an inhibitor of the sodiumglucose cotransporter 2 (SGLT2) protein, is one of the most recently developed antidiabetic drugs for treating type 2 diabetes mellitus (T2DM)
When approved options may arrive CagriSema may reach the market within the next one to two years based on current trial timelines and regulatory trajectories
Available in 60 softgels
Empower dispensed 19,990 total prescriptions through Defy in the first quarter of 2024, far more prescriptions than any other client, the dashboard shows
US$ 29.54
US$ 21.42
US$ 22.98
US$ 29.94
US$ 26.62
US$ 21.99
